The European and Developing Countries Clinical Trials Partnership (EDCTP), have awarded the Malaria Epidemiology Group at the Malawi-Liverpool-Wellcome Trust (MLW) a “Coordination & Support Actions” grant to support the translation of findings from the previously EDCTP-funded ADAPT 1 & 2 and ADJusT trials towards treatment policy and health impact.

The project called IMPACT aims at reviewing and raising awareness of dose optimisation research priorities for key risk groups among researchers, funders and control programmes. The work will focus on the antimalarial dihydroartemisinin-piperaquine (DHA-PPQ), one of the World Health Organization (WHO) recommended drugs to treat uncomplicated malaria.